ArticleJournal of clinical pathology2014
Expression of EpCAM(MF) and EpCAM(MT) variants in human carcinomas.
Article in Journal of clinical pathology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 2 syntheses or guidelines pooled it, 47 citations in OpenAlex.
- Pooled it
- Pooled it
- Targeted therapies in bladder cancer: signaling pathways, applications, and challenges.MedComm · 2023Review
- EpCAM tumor specificity and proteoform patterns in urothelial cancer.Journal of cancer research and clinical oncology · 2023Article
- EpCAM expression negatively regulates E-cadherin function in colorectal carcinomas.Ecancermedicalscience · 2023Article
- Synthesis of doxorubicin-loaded peptosomes hybridized with gold nanorod for targeted drug delivery and CT imaging of metastatic breast cancer.Journal of nanobiotechnology · 2022Article
- A novel strategy for treatment of bladder cancer: Antibody-drug conjugates.Investigative and clinical urology · 2022Review
- Biomarker identification of chronic atrophic gastritis and its potential drug analysis.Frontiers in gastroenterology (Lausanne, Switzerland) · 2022Article
- Recent advances in immune therapies for gastric cancer.Cancer gene therapy · 2021Review
- A fully automated assay to detect the expression of pan-cytokeratins and of EML4-ALK fusion protein in circulating tumour cells (CTCs) predicts outcome of non-small cell lung cancer (NSCLC) patients.Translational lung cancer research · 2021Article
- Hepatocellular carcinoma: Intratumoral EpCAM-positive cancer stem cell heterogeneity identifies high-risk tumor subtype.BMC cancer · 2020Article
- Estrogen and Progesterone Expression in Colorectal Carcinoma: A Clinicopathological Study.Asian Pacific journal of cancer prevention : APJCP · 2020Article
- The Diagnostic Value of Arginase-1, FTCD, and MOC-31 Expression in Early Detection of Hepatocellular Carcinoma (HCC) and in Differentiation Between HCC and Metastatic Adenocarcinoma to the Liver.Journal of gastrointestinal cancer · 2020Article
- Anti-EpCAM antibodies for detection of metastatic carcinoma in effusions and peritoneal wash.Oncology letters · 2019Article
- Establishment of pancreatic cancer patient-derived xenograft models and comparison of the differences among the generations.American journal of translational research · 2019Article
- Overexpression of epithelial cell adhesion molecule as a predictor of poor outcome in patients with hepatocellular carcinoma.Experimental and therapeutic medicine · 2018Article
- Antibody-Drug Conjugates in Bladder Cancer.Bladder cancer (Amsterdam, Netherlands) · 2018Review
- Binary-blend fibber-based capture assay of circulating tumor cells for clinical diagnosis of colorectal cancer.Journal of nanobiotechnology · 2018Article
- Isolation of circulating tumor cells from pancreatic cancer by automated filtration.Oncotarget · 2017Article
- Hepatic transcriptomic alterations for N,N-dimethyl-p-toluidine (DMPT) and p-toluidine after 5-day exposure in rats.Archives of toxicology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsRegulated intramembrane proteolysis has been shown to be an important mechanism for oncogenic activation of epithelial cell adhesion molecule (EpCAM) through nuclear translocation of the intracellular domain EpICD. Recent studies have identified new membrane-bound EpCAM variants. To evaluate the prevalence of two membranous EpCAM variants in human tumours, we performed a large-scale expression analysis using specific antibodies against the extracellular domain EpEX (MOC-31 clone) and the intracellular domain EpICD (9-2 clone) of the EpCAM antigen by immunohistochemistry. MATERIAL AND
methodsTwo multi-tissue microarrays (TMA) series containing 1564 tissue samples each of 53 different histological tumour types were stained and compared. One TMA was stained for EpEX and one for EpICD. Membranous full-length EpCAM (EpCAM(MF)) expression in tissues was defined by the expression of EpEX and EpICD, while the truncated variant of EpCAM (EpCAM(MT)) was characterised by a significant loss of membranous EpICD expression compared with EpEX expression.
resultsWe defined tumours with high EpCAM(MT) expression (ie, cancers of the endometrium and bladder), tumours with intermediate (ie, gastric, pancreatic, colorectal and oesophageal cancer) and tumours with low rates of expression of the EpCAM(MT) variant (ie, lung, ovarian, gallbladder, breast and prostate cancer).
conclusionsOur results indicate that loss of membranous EpICD expression is a common event in human epithelial carcinomas, arguing for the expression of different degrees of EpCAM(MF) and EpCAM(MT) variants across the most important tumour entities. Future studies evaluating the prognostic and predictive role of these variants in human malignancies, especially in patients treated with EpCAM-specific antibodies, are clearly warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.